Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPagakrong Lumbiganonen_US
dc.contributor.authorPope Kosalaraksaen_US
dc.contributor.authorTorsak Bunupuradahen_US
dc.contributor.authorDavid Boettigeren_US
dc.contributor.authorVonthanak Saphonnen_US
dc.contributor.authorKhanh H. Truongen_US
dc.contributor.authorNia Kurniatien_US
dc.contributor.authorRawiwan Hansudewechakulen_US
dc.contributor.authorViet C. Doen_US
dc.contributor.authorTavitiya Sudjaritruken_US
dc.contributor.authorNagalingeswaran Kumarasamyen_US
dc.contributor.authorNantakar Kongstanen_US
dc.contributor.authorNik K.N. Yusoffen_US
dc.contributor.authorLam V. Nguyenen_US
dc.contributor.authorDewi K. Watien_US
dc.contributor.authorKamarul Razalien_US
dc.contributor.authorAnnette H. Sohnen_US
dc.contributor.authorAzar Kariminiaen_US
dc.description.abstractBackground: Severe anemia is common among children infected with human immunodeficiency virus (HIV). The choice of antiretroviral (ART) regimen needs careful consideration. No information is available regarding the initial ART regimens used in the Asia-Pacific region and the rate of switch of ART regimens in HIV-infected children with severe anemia. Objectives: To study the initial ART regimens and the rate of switch of ART regimens used during the first 36 months in HIV-infected children with severe anemia and to evaluate their clinical and laboratory outcomes. Methods: We analyzed regional cohort data of 130 Asian children aged <18 years with baseline severe anemia (hemoglobin <7.5 g/dl) who started antiretroviral therapy (ART) between January 2003 and September 2013. Results: At ART initiation, median age was 3.5 years old (interquartile range (IQR) 1.7 to 6.3) and median hemoglobin was 6.7 g/dL (IQR 5.9-7.1, range 3.0-7.4). Initial ART regimens included stavudine (85.4%), zidovudine (13.8%), and abacavir (0.8%). In 81 children with available hemoglobin data after 6 months of ART, 90% recovered from severe anemia with a median hemoglobin of 10.7 g/dL (IQR 9.6-11.7, range 4.4-13.5). Those starting AZT-based ART had a mortality rate of 10.8 (95% confidence interval (CI) 4.8-23.9) per 100 patient-years compared to 2.7 (95% CI 1.6-4.6) per 100 patient-years among those who started d4T-based ART. Conclusions: With the phase-out of stavudine, age-appropriate non-zidovudine options are needed for younger Asian children with severe anemia.en_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleHIV-infected children in the Asia-Pacific region with baseline severe anemia: Antiretroviral therapy and outcomesen_US
article.title.sourcetitleAsian Biomedicineen_US
article.volume10en_US Kaen Universityen_US HIV Netherlands Australia Thailand Research Collaborationen_US of New South Wales (UNSW) Australiaen_US Center for HIV/AIDSen_US's Hospital 1en_US of Indonesia, RSUPN Dr. Cipto Mangunkusumoen_US Prachanukroh Hospitalen_US's Hospital 2en_US Mai Universityen_US Medical Centre Indiaen_US Universityen_US Raja Perempuan Zainab IIen_US Hospital of Pediatrics Hanoien_US Udayanaen_US Lumpur Hospitalen_US - The Foundation for AIDS Researchen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.